Trial Profile
The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Cocaine-related disorders; Kidney disorders; Major depressive disorder
- Focus Adverse reactions
- Sponsors Alkermes plc
- 20 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 30 Jun 2015 New trial record